Hungry bone syndrome: biochemical and clinical risk factors

2019 ◽  
Vol 55 (1) ◽  
pp. 43-48
Author(s):  
Ewa Kozłowska ◽  
Olga Ciepiela

Primary hyperparathyroidismremains the first cause of hypercalcaemia. Parathyroid surgery is the most efficient treatment of primary hyperparathyroidism, however surgery entails risk of development of a Hungry Bone Syndrome (HBS) – rapid, profound, and prolonged hypocalcaemia. The risk factors of HBS are significantly elevated calcium and PTH concentration in plasma, large tumor mass, previously diagnosed osteoporosis and age over 61 years old before surgery. Pre-surgery supplementation of vitamin D3 and long-term therapy with bisphosphonate allows for more efficient control of hypocalcemia and bone metabolism after surgery.

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Ekaterina Parshina ◽  
Aleksei Zulkarnaev ◽  
Konstantin Novokshonov ◽  
Pavel Kislyy ◽  
Alexey Tolkach ◽  
...  

Abstract Background and Aims Hungry bone syndrome (HBS) and postoperative hypoparathyroidism both are important postoperative complications after parathyroidectomy (PTx) for severe secondary hyperparathyroidism (SHPT). There is still a lack of data in the literature concerning associated risk factors of the prolonged HBS and hypoparathyroidism after PTx. We aimed to explore the risk factors for HBS and postoperative persistent hypoparathyroidism development in a long-term period after surgery. Method We performed a retrospective analysis of 55 severe SHPT patients who underwent subtotal PTx or total PTx+AT in our clinic between 2011 and 2015 with follow-up period not less than 12 months. A general cohort was divided into subgroups according to their laboratory parameters in a year after PTx. Prolonged HBS was defined as a total serum calcium concentration less than 2,1 mmol/l after 1 year from surgery. Postoperative hypoparathyroidism was defined as a iPTH value less than 10 pg/mL after one year from surgery. Results In terms of prolonged HBS persistence a general cohort of 55 patients was divided into two subgroups: a HBS group of 27 patients (49,1%) with mean age of 45,6 ± 9,02 years and a non-HBS group of 49,6 patients (50,9%) with mean age of 45,6 ± 10,8 years. Mean dialysis vintage for HBS and non-HBS groups was 107,8 ± 52,4 and 97,4± 54,5 months, respectively. The PTH level dropped significantly in both groups on the 1st day after surgery when compared with preoperative values: from 134 [92,7-186] to 5,0 [2,1–17,7] pmol/l in non-HBS group (p<0,001) and from 126 [101-223] to 4,1 [1,5-14,5] pmol/l in HBS group (p<0,001). The immediate ionized calcium levels also decreased significantly in both groups: from 1,26 [1,2-1,3] to 0,89 [0,79-1,09] in non-HBS group (p<0,001), and from 1,2 [1,11-1,29] to 0,88 [0,8-1,0] in HBS group (p<0,001). In univariate analysis the postoperative iPTH showed no significant difference between the HBS and non-HBS groups (p= 0,614) as well as ionized Ca level (p= 0,5653), difference of PTH before/after surgery (ΔPTH) (p= 0,9133), age (p= 0,2575) and dialysis vintage (p= 0,6165). Neither gender (RR 0,75 [0,44; 1,277]; p = 0.4088), nor type of surgery (RR 0,81 [0,45; 1,456]; p = 0.5815) were associated with the long-term HBS persistence. For 51 patients data of iPTH level in a 1 year after PTx were available; 21 patients (41,2 %) were included in the postoperative persistent hypoparathyroidism-positive group (hypoPT-positive), and 30 patients (58,8%) were included in the postoperative persistent hypoparathroidism-negative (hypoPT-negative) group. In both hypoPT-positive and hypoPT-negative groups postoperative iPTH levels were decreased after surgery with significant difference being compared between groups (1,0 [0,8-2,5] vs 12,6 [3,7-17,7] pmol/l, respectively; p= 0,0001). We observed a moderate positive correlation between iPTH levels on the 1st postoperative day and in a 1 year after PTx (ρ=0,548 [95% CI 0,314; 0,72]; p<0,0001). Type of surgery was not associated with increased risk of prolonged hypoparathyroidism (RR=1.03 [0,569; 1,866]; p=0.922). Conclusion Prolonged persistence of HBS and postoperative hypoparathyroidism are common after PTx in patients with SHPT regardless the type of surgery. Neither laboratory (postoperative iPTH, ΔPTH, ionized Ca), nor demographic (gender, age, dialysis vintage) factors were not associated with HBS persistence in a long-term period after PTx. Only serum iPTH level on the 1st day after PTx is associated with prolonged hypoparathyroidism after surgery.


2020 ◽  
Vol 2 (1) ◽  
pp. 62-65
Author(s):  
M.R. Rahmetova ◽  

Purpose: to study the influence of risk factors on the development of cardiovascular complications in patients with diabetes mellitus and to evaluate the effectiveness of treatment depending on the effect of certain factors. Materials and methods. Westudied 23 patients with type 2 diabetes mellitus with chronic cardiovascular complications, who were prescribed long-term therapy for diabetes and cardiovascular complications. Patients were offered questionnaires with questions about the prescribed treatment, the actual treatment received and the reasons for the violation of the recommendations.


Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 27-28
Author(s):  
Jade Jones ◽  
Binsah Susan George ◽  
Christine B Peterson ◽  
Thao-Mi Tran Ha ◽  
Jan A. Burger ◽  
...  

Long-term therapy with ibrutinib is commonly used to treat patients with chronic lymphocytic leukemia (CLL). Hypertension (HTN) has been reported as a side effect of ibrutinib in 21- 78% of patients treated, but this was after short exposure (29-30 months). Limited information is available regarding the development of cardiovascular and renal complications in these patients. In this study, we explored the effect of long-term ibrutinib exposure on blood pressure (BP) and on the development of cardiovascular and renal complications. Three hundred and one patients with CLL were included in this analysis. Patients were participants enrolled on ibrutinib-based clinical trials from 2010 to 2017. Collected information included patient demographics, comorbidities, tobacco use, and antihypertensive therapy. BP was evaluated at baseline, at 1 month, then every 3 months for one year followed by every 2 years for a total of 5 years. Development of HTN was characterized as a systolic BP (SBP) of ≥ 130 mmHg and/or diastolic BP (DBP) ≥ 80 mmHg on two separate visits with no prior diagnosis of HTN or use of antihypertensive therapy. We also recorded any change in systolic or diastolic BP ≥10 mmHg. Univariate logistic regression and linear regression analysis was performed to assess the relationship of HTN risk factors and new or worsened HTN. Patients' characteristics are described in the table 1 below. Median follow-up was 3 years (range 3 months-5 years). Pre-existing HTN was present in 68% of patients, and 47% were on antihypertensive therapy prior to ibrutinib. New HTN developed in 71% of patients without prior diagnosis of HTN. Worsening HTN developed in 56% of patients who had HTN at baseline. However, only 37% of them were started on antihypertensive therapy or received additional antihypertensive therapy. Of the patients who experienced an increase in BP, 29% experienced isolated systolic HTN. Median SBP was 131 mmHg at baseline, 132 mmHg at 1 month, 137 mmHg at 3 months, 137 mmHg at 6 months, 139 mmHg at 12 months, 140.5 mmHg at 3 years, and 139.5 mmHg at 5 years (mean increase in SBP: 8.15, 95% CI: 5.9 - 10.4). In patients whose SBP was < 130 mmHg at baseline the median SBP was 118 mmHg at baseline, 122.5 mmHg at 1 month, 131 mmHg at 3 months, 130 mmHg at 6 months, 134 mmHg at 12 months, 133.5 mmHg at 3 years and 138 mmHg at 5 years (mean increase in SBP: 17.3, p=0.001). Seventy-nine percent of patients experienced an increase in SBP ≥10 mmHg. The median time to onset of new or worsened HTN (50% cumulative incidence) was 12 months. New HTN on ibrutinib was not associated with tobacco use, obesity, chronic kidney disease, or obstructive sleep apnea (p > 0.05). Development of cardiovascular and renal complications associated with HTN were also studied. New or worsening atrial fibrillation occurred in 17.3% of patients, new or worsening congestive heart failure in 3.0% of patients, new or clinically significant worse coronary artery disease was documented in 8.0% of patients, ischemic stroke occurred in 3.3% of patients and intracerebral hemorrhages occurred in 2.7% of patients. New or worsening chronic kidney disease was observed in 14.3% of patients. Based on our findings, an increase in BP is common in patients with CLL being treated with long-term ibrutinib therapy. We observed that HTN in these patients is persistent, progressive and independent of other common risk factors for HTN. A proportion of patients developed cardiovascular complications during treatment and worsening renal function. Only 37% of patients in our study received new or additional antihypertensive medications, which may account for the persistent BP elevation and suggests a suboptimal HTN management in these patients. Disclosures Burger: Pharmacyclics, an AbbVie company: Consultancy, Research Funding, Speakers Bureau; Janssen Pharmaceuticals: Consultancy, Speakers Bureau; Gilead Sciences: Consultancy, Research Funding; Beigene: Research Funding, Speakers Bureau; AstraZeneca: Consultancy; TG Therapeutics: Research Funding, Speakers Bureau. Jain:BeiGene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; TG Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Cellectis: Research Funding; BMS: Research Funding; Pfizer: Research Funding; Servier: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Research Funding; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Aprea Therapeutics: Research Funding; Precision Bioscienes: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; ADC Therapeutics: Research Funding; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Fate Therapeutics: Research Funding; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.


1997 ◽  
Vol 17 (03) ◽  
pp. 161-162
Author(s):  
Thomas Hyers

SummaryProblems with unfractionated heparin as an antithrombotic have led to the development of new therapeutic agents. Of these, low molecular weight heparin shows great promise and has led to out-patient therapy of DVT/PE in selected patients. Oral anticoagulants remain the choice for long-term therapy. More cost-effective ways to give oral anticoagulants are needed.


2007 ◽  
Vol 40 (05) ◽  
Author(s):  
M Kungel ◽  
A Engelhardt ◽  
T Spevakné-Göröcs ◽  
M Ebrecht ◽  
C Werner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document